Add like
Add dislike
Add to saved papers

The impact of the preventive medical message on intention to change behavior.

Clinicians counsel patients to adopt behaviors to reduce health risks. We studied, in the case of coronary artery disease, the impact of those parts of the preventive medical message clinicians can vary. We asked 150 French people (86 aged 20-30, 64 aged 60-80) to rate their intention to adopt a specific behavior-take medication, change their diet, or start exercising-in 64 scenarios, composed of two severities of disease manifestations (angina pectoris or heart attack); four levels of its probability of occurrence (5, 10, 15, or 20%) and the associated time horizon (20, 15, 10, or 5 years, respectively); and two levels of controllability of the risk (entirely under your control or not much you can do to reduce it). We found that all four parts of the message had significant main effects and did not interact with each other. Older participants had greater intention to adopt preventive behavior when the time horizon was short and younger ones when it was long. The only gender effect was that older women were more sensitive to time horizon. The message's parts were combined additively. Participants intended to change behavior even when told this would be of little use. We concluded that clinicians should, when possible, discuss all key parts of the preventive medical message; that they can, however, focus on one without reducing the others' impact; and that, at least for outcomes such as angina and heart attack, they should speak of risk with young patients using a long time horizon, with old patients using a short time horizon.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app